A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Oct 19, 2016

Termination of Business Transfer Discussion with Kaketsuken

Tokyo, October 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that Astellas has terminated the discussion with the...

Read more about Termination of Business Transfer Discussion with Kaketsuken
Oct 14, 2016

World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports

MONTREAL and TOKYO, 14 October 2016 – The World Anti-Doping Agency (President: Sir Craig Reedie, “WADA”) and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka,...

Read more about World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
Oct 13, 2016

FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN

North Brunswick, N.J. and Tokyo, October, 12, 2016 – Chromocell Corporation and Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Read more about FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Oct 11, 2016

Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care　-Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER-

NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...

Read more about Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care　-Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER-
Oct 11, 2016

Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care

Three C3 Prize winners awarded a total of $100,000 in grants and a membership to MATTER

NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...

Read more about Astellas Oncology Announces Winning C3 Prize™ Ideas in Virtual Reality, Online Patient Support and Fatigue-Reducing Light Therapy to Change Cancer Care
Oct 7, 2016

Astellas Filed Lawsuit against Patent Infringement of Myrbetriq® in the United States

Tokyo, Japan, October 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) and its subsidiaries jointly filed a lawsuit against Actavis Elizabeth LLC...

Read more about Astellas Filed Lawsuit against Patent Infringement of Myrbetriq® in the United States
Oct 5, 2016

Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund

Tokyo, October 5, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the "Flying Star Fund," a social contribution fund run by its employees,...

Read more about Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund
Sep 28, 2016

Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area

Osaka and Tokyo (Japan), September 28, 2016 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office:...

Read more about Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area
Sep 28, 2016

Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, September 28, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it received a marketing approval of Kiklin® Granules 86.2%...

Read more about Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
Sep 28, 2016

Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination-

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...

Read more about Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB/CCB/diuretic three ingredients combination-
Sep 19, 2016

Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients

SAN DIEGO and TOKYO - September 19, 2016 – Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. (TOKYO: 4503) today announced topline results from a randomized, double-blind,...

Read more about Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
Sep 16, 2016

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year

Tokyo, September 16, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year as an index...

Read more about Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year
Sep 7, 2016

Astellas donates ambulances on First Aid Day (September 9)

Tokyo, September 7, 2016 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it will donate three high-standard ambulances on First Aid Day...

Read more about Astellas donates ambulances on First Aid Day (September 9)
Aug 23, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Aug 19, 2016

Astellas and World Transplant Games Federation Announce Launch of Fit for Life! to Promote Physical Activity in Transplant Recipients Worldwide

HONG KONG August 19, 2016 -- Astellas Pharma Inc. (TSE: 4503, “Astellas”) and the World Transplant Games Federation (WTGF) today announced the launch of Fit for Life!, a global program to help...

Read more about Astellas and World Transplant Games Federation Announce Launch of Fit for Life! to Promote Physical Activity in Transplant Recipients Worldwide
Aug 9, 2016

Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan

Tokyo, August 9, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application to the Ministry of Health,...

Read more about Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan
Aug 4, 2016

Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara

Read more about Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara
Jul 29, 2016

Astellas Reports First Quarter Financial Results of FY2016

Read more about Astellas Reports First Quarter Financial Results of FY2016
Jul 29, 2016

Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital

Tokyo and San Francisco, July 29, 2016 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce...

Read more about Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital
Jul 27, 2016

CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS

Cytokinetics to Receive $65 Million in Upfront Payments and $30 Million in Additional Sponsored R&D; Potential for More than $100 Million in Payments Associated with the Exercise of the Option

SOUTH SAN FRANCISCO, Calif. and TOKYO, Japan, July 27, 2016 – Cytokinetics, Inc. (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that...

Read more about CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN ALS
Jul 25, 2016

Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan

Read more about Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
Jul 6, 2016

Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year

Tokyo, July 6, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the fifth consecutive year to be included in the...

Read more about Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year
Jun 23, 2016

The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine

Tokyo, June 23, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...

Read more about The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreement for Rice-Based Oral Vaccine
Jun 2, 2016

ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

Read more about ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
May 31, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
May 24, 2016

Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.

-First company established under Vitesse Biologics, an innovative collaboration formed by Baxalta, Mayo Clinic and Velocity Pharmaceutical Development

BANNOCKBURN, Ill., SAN FRANCISCO, Calif., and TOKYO, Japan, May 24, 2016 – Baxalta Incorporated (NYSE: BXLT), Velocity Pharmaceutical Development, LLC (VPD) and Astellas Pharma Inc. (TSE:4503)...

Read more about Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
May 23, 2016

Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults

Tokyo and Osaka, Japan, May 23, 2016 ---Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; "Astellas"), Daiichi Sankyo Company, Limited (President and...

Read more about Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults
May 23, 2016

THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT THE ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY (JDS 2016)

Read more about THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT THE ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY (JDS 2016)
May 11, 2016

Astellas Announces Cancellation of Treasury Shares

Read more about Astellas Announces Cancellation of Treasury Shares
May 11, 2016

Notice Regarding the Continuation of a Performance-linked Stock Compensation Scheme

Read more about Notice Regarding the Continuation of a Performance-linked Stock Compensation Scheme
Apr 27, 2016

Astellas Co-sponsors C3 Prize

Tokyo, April 27, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that its subsidiary, Astellas US LLC is co-sponsoring the C3 (Changing Cancer...

Read more about Astellas Co-sponsors C3 Prize
Apr 27, 2016

Astellas Announces Changes to Representative Director and Audit & Supervisory Board Member

Read more about Astellas Announces Changes to Representative Director and Audit & Supervisory Board Member
Apr 21, 2016

AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL

FIrst PCSK9 Inhibitor in Japan

TOKYO (April 21, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL
Apr 18, 2016

Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts

Tokyo, April 18, 2016– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of the 2016...

Read more about Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts
Apr 8, 2016

Certain media coverage related to Astellas

Tokyo, April 8, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that certain media coverage related to transfer of business of the...

Read more about Certain media coverage related to Astellas
Apr 7, 2016

CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)

-- TERRAIN Trial Showed Statistically Significant PFS Improvement with Enzalutamide Versus Bicalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer --

Read more about CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide)
Apr 1, 2016

Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases

Tokyo, April 1, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") today announced that it has signed a new collaborative research agreement with the...

Read more about Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treatment of Chagas' disease, one of Neglected Tropical Diseases
Apr 1, 2016

Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asia Regions

Read more about Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asia Regions
Apr 1, 2016

Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business

Read more about Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business
Mar 29, 2016

Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries

Tokyo and Osaka, March 29, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitsubishi Tanabe Pharma Corporation (President and Representative Director:...

Read more about Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
Mar 25, 2016

Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer

Read more about Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Mar 22, 2016

POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS

BRIDGE Study Met Primary and All Secondary Endpoints

TOKYO (March 22, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Eiichi Takahashi, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS
Mar 16, 2016

Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women

- First time for a Pharmaceutical Company to be named to both Diversity Management Selection 100 and Nadeshiko Brand -

Read more about Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women
Mar 4, 2016

Astellas Announces Personnel Changes

Read more about Astellas Announces Personnel Changes
Mar 2, 2016

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Mar 1, 2016

Astellas Announces Personnel Changes and Organizational Change

Read more about Astellas Announces Personnel Changes and Organizational Change
Mar 1, 2016

Astellas Announces Management Structure Change

Read more about Astellas Announces Management Structure Change
Feb 29, 2016

Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

Read more about Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan
Feb 24, 2016

Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan

Tokyo, February 24, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a new drug application for a guanylate...

Read more about Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japan
Feb 22, 2016

FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide

Read more about FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
Feb 10, 2016

Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries

Read more about Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidaries
Feb 1, 2016

Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa

Tokyo and Miyagi, February 1st, 2016 - Astellas Pharma Inc. (TSE : 4503, President and CEO : Yoshihiko Hatanaka, “Astellas”) and CLINO Corporation (President : Noriaki Satake, “CLINO”)...

Read more about Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa
Jan 29, 2016

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Jan 23, 2016

POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

FRAME Study Met All Primary Endpoints by Reducing the Incidence of New Vertebral Fracture Through 12 and 24 Months

Read more about POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN OSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
Jan 22, 2016

REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL

Important Milestone for Certain Japanese Patients With Uncontrolled LDL Cholesterol

Read more about REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL
Jan 22, 2016

Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - ASTELLAS IS COMMITTED TO TRANSACTION, ACQUISITION OF OCATA IS A STRATEGIC PRIORITY -

Tokyo and Massachusetts, January 22, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:...

Read more about Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - ASTELLAS IS COMMITTED TO TRANSACTION, ACQUISITION OF OCATA IS A STRATEGIC PRIORITY -
Jan 7, 2016

Extension of agreement on Telmisartan (Micardis® family)

Read more about Extension of agreement on Telmisartan (Micardis® family)
Dec 18, 2015

Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Tokyo and Massachusetts, December 18, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO:...

Read more about Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Dec 10, 2015

Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy

Houston and Tokyo, December 10, 2015 - Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM, “Bellicum”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that Agensys, Inc....

Read more about Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Dec 2, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Dec 1, 2015

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
Dec 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Nov 30, 2015

Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan

Read more about Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
Nov 20, 2015

Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics

Tokyo, November 20, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has commenced, through its indirect wholly-owned...

Read more about Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Nov 18, 2015

Presentation for Astellas to Acquire Ocata Therapeutics

Astellas added minor revisions into the presentation for Astellas to acquire Ocata Therapeutics which was disclosed on November 10th, 2015. Presentation for Astellas to Acquire Ocata Therapeutics...

Read more about Presentation for Astellas to Acquire Ocata Therapeutics
Nov 13, 2015

Named to 2015 Climate Disclosure Leadership Index -Recognized for perfect disclosure score for climate change information -

Tokyo, November 13, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been named for the first time to the CDP1) Japan 500 Climate...

Read more about Named to 2015 Climate Disclosure Leadership Index -Recognized for perfect disclosure score for climate change information -
Nov 10, 2015

The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol, Announced at 2015 ACR/ARHP Annual Meeting

- The Clinical benefit of initial 1-year CZP treatment was maintained after discontinuation up to another 1-year -

Read more about The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol, Announced at 2015 ACR/ARHP Annual Meeting
Nov 10, 2015

Acquisition of Ocata Therapeutics

New Step Forward in Ophthalmology with Cell Therapy Approach

Read more about Acquisition of Ocata Therapeutics
Oct 30, 2015

Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business

Read more about Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business
Oct 28, 2015

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Oct 28, 2015

Astellas Initiates Phase 3 Registration Trial of gilterritnib (ASP2215) in Relapsed of Refractory Acute Myeloid Leukemia Patients

Read more about Astellas Initiates Phase 3 Registration Trial of gilterritnib (ASP2215) in Relapsed of Refractory Acute Myeloid Leukemia Patients
Oct 9, 2015

Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease

Hershey, PA & Rockville, MD and Tokyo, Japan, October 9, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...

Read more about Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease
Oct 5, 2015

Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund

Read more about Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund
Sep 30, 2015

Submission of a Supplemental New Drug Application for ASP1585 Granule,a Treatment for Hyperphosphatemia, in Japan

Tokyo, September 30, 2015 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a supplemental new drug application for...

Read more about Submission of a Supplemental New Drug Application for ASP1585 Granule,a Treatment for Hyperphosphatemia, in Japan
Sep 30, 2015

Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

Tokyo and North Brunswick, N.J., Sept 30th, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Chromocell Corporation (CEO: Christian Kopfli,...

Read more about Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
Sep 18, 2015

Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year

Read more about Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year
Sep 17, 2015

Astellas Supports Relief Efforts Following Typhoon in Eastern and Northern Japan

Read more about Astellas Supports Relief Efforts Following Typhoon in Eastern and Northern Japan
Sep 8, 2015

Astellas Named to FTSE4Good Sustainability Index for the Fourth Consecutive Year

Read more about Astellas Named to FTSE4Good Sustainability Index for the Fourth Consecutive Year
Sep 7, 2015

Astellas donates ambulances on First-Aid Day (September 9)

-45th donation since 1970, totaling 234 ambulances

Read more about Astellas donates ambulances on First-Aid Day (September 9)
Aug 27, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Aug 20, 2015

Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan

Read more about Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan
Jul 31, 2015

Astellas Establishes New Real World Informatics and Analytics Function

Tokyo, Japan, July 31, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, collectively with its affiliates, hereinafter called “Astellas”) announced the launch of the Real...

Read more about Astellas Establishes New Real World Informatics and Analytics Function
Jul 31, 2015

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Jul 30, 2015

Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections

NORTHBROOK, Ill., July 30, 2015 – Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole,...

Read more about Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections
Jul 23, 2015

Astellas Initiates Collaborative Research with National Institute of Advanced Industrial Science and Technology by Utilizing Highly Advanced IT Drug-Discovery Technologies

- Aiming for early discovery of compounds in the areas of Ophthalmology and Nephrology by merging approximately 10,000 of protein-ligand complex structural information and highly advanced IT drug-discovery technologies -

Read more about Astellas Initiates Collaborative Research with National Institute of Advanced Industrial Science and Technology by Utilizing Highly Advanced IT Drug-Discovery Technologies
Jul 22, 2015

“Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice” published in “Stem Cells Translational Medicine” on line

Read more about “Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice” published in “Stem Cells Translational Medicine” on line
Jul 16, 2015

The Netherlands Decorates Masafumi Nogimori, Representative Director and Chairman of Astellas with "Officer in the Order of Oranje-Nassau" Royal Decoration

Read more about The Netherlands Decorates Masafumi Nogimori, Representative Director and Chairman of Astellas with "Officer in the Order of Oranje-Nassau" Royal Decoration
Jul 13, 2015

Notice of Completion of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares
Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Jun 15, 2015

Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology

Read more about Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology
Jun 2, 2015

Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -

Astellas Pharma Inc. (“Astellas”; TSE 4503, headquarters: Tokyo; President and CEO Yoshihiko Hatanaka) and Anokion SA (“Anokion“, headquarters: Lausanne; Chairman Jeffrey A. Hubbell) today...

Read more about Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -
Jun 2, 2015

NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

TOKYO and NORTHBROOK, Ill. – June 1, 2015 – Astellas Pharma Inc. (Tokyo: 4503) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for...

Read more about NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Jun 1, 2015

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
May 30, 2015

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Read more about Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 27, 2015

Strategic Plan 2015-2017

Building Resilience for Sustainable Growth

Read more about Strategic Plan 2015-2017
May 26, 2015

Astellas: Strategic Plan 2015-2017

Read more about Astellas: Strategic Plan 2015-2017
May 26, 2015

Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan

Read more about Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan

Show per page

Discover more

Media contacts

Return to media homepage

Subscribe to news alerts

Choose Language

News